PCI – 7th June 2024
Thermofisher: Thu 29 February 2024, 11:15

Current Edition

Cell and Gene Therapy

Upcoming Events

Cell 2025 – 30.05.2025
Cell Leaders Awards – 30.05.2025
Biotechnology Show 2025: 20th January 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault – 18.03.2025
Biopharma Group – 19th March 2025

Pfizer, BioNTech to seek full approval as COVID-19 vaccine efficacy holds up in young teens

The results disclosed by Pfizer and BioNTech on Monday could support full approvals in the U.S. and elsewhere, which in turn could help bolster vaccination rates among adolescents and young teenagers. About 51% of 12- to 17-year-olds in the U.S. were fully vaccinated as of Nov. 21, the lowest of any age group aside from young kids who just became eligible this month, according to the Centers for Disease Control and Prevention.

Vaccination rates among U.S. adolescents spiked shortly after authorization in May but have plateaued since. Roughly 30% of parents polled by the Kaiser Family Foundation recently said they would “definitely not” get their kids in that age group vaccinated, the highest of any point since Pfizer’s shot became available.

Younger, healthier people are generally able to avoid the worst effects of COVID-19 better than those who are older or have weaker immune systems. Additionally, rates of a type of heart inflammation called myocarditis that’s been associated in rare cases with Pfizer’s and Moderna’s vaccines are greatest in teenage boys and young men.

But younger people can trigger outbreaks that close schools, cause parents to miss work or spread to more vulnerable adults. The risk-benefit calculation among adolescents may also change as infection rates, which have recently begun to climb, could increase further as people gather indoors and protection wanes for adults who haven’t yet been boosted.

The new results show Pfizer’s shot maintains strong protection through at least four months, even during the spread of the infectious delta variant. Efficacy results were collected through September, the two companies said. The side effect profile was “generally consistent” with what’s been seen so far in clinical testing, though Pfizer and BioNTech didn’t say whether any myocarditis was observed.

Still, though protection has held up through four months, it’s unclear whether 12- or 15-year-olds will also need a booster shot. Immunity against infection and mild COVID-19 seems to wane for adults after about six months, leading the U.S. and other countries to authorize additional doses for much of their adult population. The Health Ministry of Israel, which has relied on Pfizer and BioNTech’s vaccine, recently advised boosters for young teenagers based on a reported reduction in vaccine effectiveness in 16- to 19-year-olds.

Pfizer and BioNTech have the only vaccine available to 12- to 15-year-olds in the U.S., and likely will for some time. The FDA recently extended a review of Moderna’s vaccine in adolescents and young teenagers to better assess the risk of myocarditis, which appears to be more common with its vaccine than with Pfizer’s.

Newcells 3 June 2024, 15:12
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
Tosoh – 29.04.25
Eppendorf – 18.03.2025
Asychem – 10.04.2025
Taconic Biosciences – 29.04.25
Steribar – 12.05.2025